Citations

Clear

4847 citation(s) found for "Tu, Eric".

Productive Replication of vif -Chimeric HIV-1 in Feline Cells
Stern, Melissa A., Hu, Chunling , Saenz, Dyana T. , Fadel, Hind J., Sims, Olivia, Peretz, Mary, Poeschla, Eric M. , Sims, Olivia L., Hu, Chunling

Mayo Clinic

Journal of Virology | May 13, 2010 | Volume: 84 | Issue: 14 | Pages: 7378-7395

10.1128/jvi.00584-10 | PMID 20463079 Get It

ABSTRACT Nonprimate animal models of HIV-1 infection are prevented by missing cellular cofactors and by antiviral actions of species-specific host defense factors. These blocks are profound in rodents but may be less abundant in certain Carnivora. Here, we enabled productive, spreading replication and passage of HIV-1 in feline cells. Feline fibroblasts, T-cell lines, and primary peripheral blood mononuclear cells supported early and late HIV-1 life cycle phases in a manner equivalent to that of human cells, except that produced virions had low infectivity. Stable expression of feline immunodeficiency virus (FIV) Vif-green fluorescent protein (GFP) in HIV-1 entry receptor-complemented feline (CrFK) cells enabled robust spreading HIV-1 replication. FIV Vif colocalized with feline APOBEC3 (fA3) proteins, targeted them for degradation, and prevented G→A hypermutation of the HIV-1 cDNA by fA3CH and fA3H. HIV-1 Vif was inactive against fA3s as expected and even paradoxically augmented restriction in some assays. In an interesting contrast, simian immunodeficiency virus SIVmac Vif had substantial anti-fA3 activities, which were complete against fA3CH and partial against fA3H. Moreover, both primate lentiviral Vifs colocalized with fA3s and could be pulled down from cell lysates by fA3CH. HIV-1 molecular clones that encode FIV Vif or SIVmac Vif (HIV-1 VF and HIV-1 VS ) were then constructed. These viruses replicated productively in HIV-1 receptor-expressing CrFK cells and could be passaged serially to uninfected cells. Thus, with the exception of entry receptors, the cat genome can supply the dependency factors needed by HIV-1, and a main restriction can be countered by vif chimerism. The results raise the possibility that the domestic cat could yield an animal model of HIV-1 infection.
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
Trojanowski, John Q. , Vandeerstichele, Hugo, Korecka, Magdalena , Clark, Christopher M. , Aisen, Paul , Petersen, Ronald C. , Blennow, Kaj , Soares, Holly , Simon, Adam J., Dean, Robert A., Siemers, Eric , Potter, William Z., Weiner, Michael W. , Jack, Clifford R. , Jagust, William J. , Shaw, Leslie M. , Initiative, Alzheimer's Disease Neuroimaging, Lewczuk, Piotr , Toga, Arthur W. , Lee, Virginia M.‐Y. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R

Mayo Clinic

Alzheimer's & Dementia | May 7, 2010 | Volume: 6 | Issue: 3 | Pages: 230-238

10.1016/j.jalz.2010.03.008 | PMID 20451871 Get It

Here, we review progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimer's disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. The Penn Biomarker Core also collaborated with other ADNI Cores to integrate data across ADNI to temporally order changes in clinical measures, imaging data, and chemical biomarkers that serve as mileposts and predictors of the conversion of normal control to MCI as well as MCI to AD, and the progression of AD. Initial CSF studies by the ADNI Biomarker Core revealed a pathological CSF biomarker signature of AD defined by the combination of Aβ1‐42 and total tau (T‐tau) that effectively delineates mild AD in the large multisite prospective clinical investigation conducted in ADNI. This signature appears to predict conversion from MCI to AD. Data fusion efforts across ADNI Cores generated a model for the temporal ordering of AD biomarkers which suggests that Aβ amyloid biomarkers become abnormal first, followed by changes in neurodegenerative biomarkers (CSF tau, F‐18 fluorodeoxyglucose‐positron emission tomography, magnetic resonance imaging) with the onset of clinical symptoms. The timing of these changes varies in individual patients due to genetic and environmental factors that increase or decrease an individual's resilience in response to progressive accumulations of AD pathologies. Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies.
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Weiner, Michael W. , Aisen, Paul , Jack, Clifford R. , Jagust, William J. , Trojanowski, John Q. , Shaw, Leslie M. , Saykin, Andrew J. , Morris, John C. , Cairns, Nigel J. , Beckett, Laurel , Walter, Sarah , Soares, Holly , Snyder, Peter J. , Siemers, Eric , Potter, William Z., Cole, Patricia E., Initiative, Alzheimer's Disease Neuroimaging, Toga, Arthur W. , Green, Robert C. , Schmidt, Mark E. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Morris, John C

Mayo Clinic

Alzheimer's & Dementia | May 7, 2010 | Volume: 6 | Issue: 3 | Pages: 202

10.1016/j.jalz.2010.03.007 | PMID 20451868 Get It

The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6‐year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C‐11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C‐11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI‐like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.
Similar T-Cell Immune Responses Induced by Group M Consensus Env Immunogens with Wild-Type or Minimum Consensus Variable Regions
Camacho, Zenaido T., Gao, Feng , Weaver, Eric A. , Weaver, Eric A

Mayo Clinic

AIDS Research and Human Retroviruses | May 3, 2010 | Volume: 26 | Issue: 5 | Pages: 577-584

10.1089/aid.2009.0258 | PMID 20438382 Get It

Evaluation of the Bio-Rad BioPlex 2200 Syphilis Multiplex Flow Immunoassay for the Detection of IgM- and IgG-Class Antitreponemal Antibodies
Gomez, Eric, Jespersen, Deborah J., Harring, Julie, Binnicker, Matthew J.

Mayo Clinic

Clinical and Vaccine Immunology | April 29, 2010 | Volume: 17 | Issue: 6 | Pages: 966-968

10.1128/cvi.00086-10 | PMID 20427627 Get It

ABSTRACT The laboratory diagnosis of syphilis is based primarily upon serologic findings. Historically, serologic testing for syphilis has relied on assays such as rapid plasma reagin, fluorescent treponemal antibody absorption, Treponema pallidum particle agglutination (TP-PA), and more recently, enzyme immunoassay (EIA). In this study, we evaluated the performance of a novel multiplex flow immunoassay (BioPlex 2200 Syphilis; Bio-Rad Laboratories, Hercules, CA) for the detection of antitreponemal IgG- and IgM-class antibodies. Serum specimens ( n = 1,008) submitted for routine treponema-specific antibody testing by syphilis IgM and IgG EIA (Trep-Chek; Phoenix-Biotech, Mississauga, Ontario, Canada) were also analyzed by the BioPlex Syphilis multiplex assay. Specimens showing discordant results were repeat tested, with further discrepancies being arbitrated by TP-PA. Compared directly to the results of EIA, the BioPlex IgG assay demonstrated 98.7% (77/78) sensitivity and 99.4% (916/930) specificity. Compared to the Trep-Chek IgM EIA, the BioPlex IgM assay showed 80% (4/5) sensitivity and 97.9% (652/666) specificity. These results indicate that the BioPlex Syphilis multiplex assay shows similar serological agreement with EIA while allowing for a fully automated random-access platform that provides faster (1.7 h for 100 samples versus 4.5 h by EIA) and higher-throughput (800 samples per 9 h versus 200 samples by EIA) analysis of the syphilis serologic response.
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
Ho, April J., Stein, Jason L. , Hua, Xue , Lee, Suh , Hibar, Derrek P., Leow, Alex , Dinov, Ivo D. , Toga, Arthur W. , Saykin, Andrew J. , Shen, Li , Pankratz, Nathan , Huentelman, Matthew J. , Craig, David W. , Gerber, Jill D., Allen, April N., Corneveaux, Jason J., Stephan, Dietrich A. , DeCarli, Charles , Dechairo, Bryan, Jack, Clifford R. , Weiner, Michael W. , Raji, Cyrus A. , Becker, James T. , Carmichael, Owen , Thompson, Paul M. , Initiative, the Alzheimer's Disease Neuroimaging, Thal, Leon J., Petersen, Ronald C., Jagust, William J. , Trojanowki, John Q., Toga, Arthur W., Gamst, Anthony, Potter, William Z., Montine, Tom, Anders, Dale, Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene E. , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Shaw, Les, Korecka, Magdalena , Toga, Arthur W., Crawford, Karen , Neu, Scott, Kornak, John , Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Vorobik, Remi, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan , Fleisher, Adam , Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Badger, Beverly, Grossman, Hillel, deToledo‐Morrell, Leyla, Bach, Julie , Duara, Ranjan , Isaacson, Richard , Strauman, Silvia, Albert, Marilyn S. , Pedroso, Julia, Toroney, Jaimie, Santi, Susan M De, Doraiswamy, P. Murali , Petrella, Jeffrey R. , Aiello, Marilyn, Clark, Christopher M. , Pham, Cassie, Nuñez, Jessica, Smith, Charles D., Given, Curtis A., Hardy, Peter , DeKosky, Steven T. , Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem , McCallum, Colleen, Cramer, Steven C. , Mulnard, Ruth A., Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Laubinger, Mary M., Bartzokis, George, Lu, Po H. , Fletcher, Rita, Parfitt, Francine, Farlow, Martin R. , Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , MacAvoy, Martha G., Bifano, Laurel A., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Graham, Simon J. , Caldwell, Curtis, Assaly, Michele, Hsiung, Ging‐Yuek Robin , Kertesz, Andrew , Trost, Dick, Bernick, Charles , Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Mesner, Scott, Aisen, Paul, Johnson, Kathleen, Behan, Kelly E., Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Ashford, Wes, Connor, Donald J., Obradov, Sanja, Jayam‐Trouth, Annapurni , Wang, Paul J. , Auchus, Alexander P. , Huang, Juebin , DeCarli, Charles , Kittur, Smita, Mirje, Seema, Borrie, Michael, Lee, T‐Y, Asthana, Sanjay , Carlsson, Cynthia M., Highum, Diane, Preda, Adrian , Tariot, Pierre N. , Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Gandy, Sam, Marenberg, Marjorie E., Rovner, Barry W. , Blank, Karen, Anderson, Karen, Santulli, Robert B. , Paré, Nadia, Williamson, Jeff D. , Raj, Balebail Ashok, Giordano, Amy T., Ott, Brian R. , Wu, Chuang‐Kuo, Cohen, Ronald A. , Wilks, Kerri, Lee, Ting‐Yim , Foroud, Tatiana , Potkin, Steven G. , López, Oscar L. , Initiative, the Alzheimer's Disease Neuroimaging, Toga, Arthur W., Beckett, Laurel , Green, Robert C. , Bernstein, Matt A. , Fox, Nick C. , Koeppe, Robert A. , Foster, Norm, Chen, Kewei , Lee, Virginia M.‐Y. , Toga, Arthur W., Harvey, Danielle , Snyder, Peter J. , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Morris, John C. , Tang, Cheuk Ying , Stern, Jessica A. , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Porsteinsson, Anton P. , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Feldman, Howard , ROGERS, John H. , Gitelman, Darren R. , Mesulam, Marsel M. , Sperling, Reisa Anne , Rentz, Dorene M. , Sabbagh, Marwan Noel , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Friedland, Robert P. , Fletcher, Evan M. , Johnson, Sterling C. , Nguyen, Dana R. , Scharre, Douglas W. , Beversdorf, David Q. , Gandy, Sam , Pearlson, Godfrey D. , Sink, Kaycee M. , Potter, Huntington , Jack, Clifford R , Saykin, Andrew J , Shen, Li , Preda, Adrian , Toga, Arthur W , Stein, Jason L , Thompson, Paul M , Hsiung, Gink-Yuek , Pankratz, Nathan

Mayo Clinic

Proceedings of the National Academy of Sciences | April 19, 2010 | Volume: 107 | Issue: 18 | Pages: 8404-8409

10.1073/pnas.0910878107 | PMID 20404173 Get It

A recently identified variant within the fat mass and obesity-associated ( FTO ) gene is carried by 46% of Western Europeans and is associated with an ~1.2 kg higher weight, on average, in adults and an ~1 cm greater waist circumference. With >1 billion overweight and 300 million obese persons worldwide, it is crucial to understand the implications of carrying this very common allele for the health of our aging population. FTO is highly expressed in the brain and elevated body mass index (BMI) is associated with brain atrophy, but it is unknown how the obesity-associated risk allele affects human brain structure. We therefore generated 3D maps of regional brain volume differences in 206 healthy elderly subjects scanned with MRI and genotyped as part of the Alzheimer's Disease Neuroimaging Initiative. We found a pattern of systematic brain volume deficits in carriers of the obesity-associated risk allele versus noncarriers. Relative to structure volumes in the mean template, FTO risk allele carriers versus noncarriers had an average brain volume difference of ~8% in the frontal lobes and 12% in the occipital lobes—these regions also showed significant volume deficits in subjects with higher BMI. These brain differences were not attributable to differences in cholesterol levels, hypertension, or the volume of white matter hyperintensities; which were not detectably higher in FTO risk allele carriers versus noncarriers. These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly.
Live-Cell Coimaging of the Genomic RNAs and Gag Proteins of Two Lentiviruses
Kemler, Iris, Meehan, Anne M. , Poeschla, Eric M.

Mayo Clinic

Journal of Virology | April 15, 2010 | Volume: 84 | Issue: 13 | Pages: 6352-6366

10.1128/jvi.00363-10 | PMID 20392841 Get It

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) Gag and genomic RNA determinants required for encapsidation are well established, but where and when encapsidation occurs in the cell is unknown. We constructed MS2 phage coat protein labeling systems to track spatial dynamics of primate and nonprimate lentiviral genomic RNAs (HIV-1 and feline immunodeficiency virus [FIV]) vis-à-vis their Gag proteins in live cells. Genomic RNAs of both lentiviral genera were observed to traffic into the cytoplasm, and this was Rev dependent. In transit, FIV Gag and genomic RNA accumulated independently of each other at the nuclear envelope, and focal colocalizations of genomic RNA with an intact packaging signal (ψ) and Gag were observed to extend outward from the cytoplasmic face. In contrast, although HIV-1 genomic RNA was detected at the nuclear envelope, HIV-1 Gag was not. For both lentiviruses, genomic RNAs were seen at the plasma membrane if and only if Gag was present and ψ was intact. In addition, HIV-1 and FIV genomes accumulated with Gag in late endosomal foci, again, only ψ dependently. Thus, lentiviral genomic RNAs require specific Gag binding to accumulate at the plasma membrane, packaged genomes cointernalize with Gag into the endosomal pathway, and plasma membrane RNA incorporation by Gag does not trigger committed lentiviral particle egress from the cell. Based on the FIV results, we hypothesize that the Gag-genome association may initiate at the nuclear envelope.
Sleeping Beauty –Mediated Somatic Mutagenesis Implicates CSF1 in the Formation of High-Grade Astrocytomas
Collier, Lara S. , Tieu, Christina, Halder, Chandralekha, Mahlum, Eric, Kollmeyer, Thomas M. , Sarkar, Gobinda , Largaespada, David A. , Jenkins, Robert B. , Bender, Aaron M. , Rodríguez, Fausto J. , Larson, Jon D. , Akagi, Keiko , Largaespada, David A. , Kollmeyer, Thomas

Mayo Clinic

Cancer Research | April 13, 2010 | Volume: 70 | Issue: 9 | Pages: 3557-3565

10.1158/0008-5472.can-09-4674 | PMID 20388773 Get It

Abstract The Sleeping Beauty (SB) transposon system has been used as an insertional mutagenesis tool to identify novel cancer genes. To identify glioma-associated genes, we evaluated tumor formation in the brain tissue from 117 transgenic mice that had undergone constitutive SB-mediated transposition. Upon analysis, 21 samples (18%) contained neoplastic tissue with features of high-grade astrocytomas. These tumors expressed glial markers and were histologically similar to human glioma. Genomic DNA from SB-induced astrocytoma tissue was extracted and transposon insertion sites were identified. Insertions in the growth factor gene Csf1 were found in 13 of the 21 tumors (62%), clustered in introns 5 and 8. Using reverse transcription-PCR, we documented increased Csf1 RNAs in tumor versus adjacent normal tissue, with the identification of transposon-terminated Csf1 mRNAs in astrocytomas with SB insertions in intron 8. Analysis of human glioblastomas revealed increased levels of Csf1 RNA and protein. Together, these results indicate that SB-insertional mutagenesis can identify high-grade astrocytoma-associated genes and they imply an important role for CSF1 in the development of these tumors. Cancer Res; 70(9); 3557–65. ©2010 AACR.
Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration
Stambolian, Dwight, Edwards, Albert O., Branham, Kari , Othman, Mohammad , Jakobsdóttir, Jóhanna , Tosakulwong, Nirubol , Pericak‐Vance, Margaret A. , Klein, Michael L. , Tan, Perciliz L. , Kanda, Atsuhiro , Kopplin, Laura J. , Li, Yanming , Augustaitis, Katherine J., Karoukis, Athanasios J., Scott, William K. , Agarwal, Anita , Kovach, Jaclyn L. , Postel, Eric A. , Brooks, Matthew, Baratz, Keith H. , Brown, William L. , Brucker, Alexander J., Orlin, Anton, Brown, Gary C. , Ho, Allen C. , Regillo, Carl D. , Donoso, Larry A., Tian, Lifeng , Kaderli, Brian, Hadley, Dexter , Hagstrom, Stephanie A. , Peachey, Neal S. , Klein, Ronald , Klein, Barbara E.K. , Gotoh, Norimoto, Yamashiro, Kenji , Ferris, Frederick L. , Fagerness, Jesen, Reynolds, Robyn, Farrer, Lindsay A. , Kim, Ivana K. , Miller, Joan W. , Cortón, Marta , Carracedo, Ángel , Sánchez‐Salorio, Manuel, Pugh, Elizabeth, Doheny, Kimberly F. , Brión, Marı́a , Weeks, Daniel E. , Zack, Donald J. , Heckenlively, John R., Yoshimura, Nagahisa , Iyengar, Sudha K. , Francis, Peter J. , Katsanis, Nicholas , Seddon, Johanna M. , Haines, Jonathan L. , Abecasis, Gonçalo R. , Swaroop, Anand , Johnson, Robert N., Ai, Everett, McDonald, H. Richard , Stolarczuk, Margaret, Pavan, Peter R., Billiris, Karina K., Iyer, Mohan , Menosky, Matthew M., Pautler, Scott E. , Millard, Sharon M., Hubbard, G. Baker , Aaberg, Thomas , DuBois, Lindy, Lyon, Alice T., Anderson-Nelson, Susan, Jampol, Lee M. , Muñana, Annie, Rozenbajgier, Zuzanna, Orth, David H., Cohen, Jack, MacCumber, Matthew, Figliulo, Celeste, Porcz, Liz, Folk, James C. , Boldt, H. Culver , Russell, Stephen R. , Ivins, Rachel, Hinz, Connie J., Bloom, Steve, Jaegers, Ken, Kritchman, Brian, Whittington, Greg K., Frederick, Albert R., Morley, Michael G., Topping, Trexler M., Davis, Heather L., Bressler, Susan B., Bressler, Neil M. , Doll, W T Jr, Trese, Michael T. , Garretson, Bruce R., Ruby, Alan, Osentoski, Tammy, Ruszczyk, Margaret, Grand, G., Joseph, Daniel P., Shah, Gaurav K. , Nobel, Ginny, Antoszyk, Andrew N., Stallings, Alison H, Singerman, Lawrence J. , Miller, David T. , Novák, Michael, Pendergast, Scott, Zegarra, Hernando, Schura, Stephanie A., Smith-Brewer, Sheila, Davidorf, Frederick H., Chorich, Louis J., Salerno, Jill, Dreyer, Richard F., Ma, Colin, Kopfer, Marcia, Wilson, David J. , Nolte, Susan K., Grunwald, Juan E. , Dunaief, Josh, Fine, Stuart L., Maguire, Albert M. , Stoltz, Robert A., McRay, Monique, Fish, Gary E., Anand, Rajiv, Spencer, Rand , Arnwine, Jean, Chandra, Suresh R., Blodi, Barbara, Gottlieb, Justin L., Ip, Michael S. , Nork, T. Michael , Perry-Raymond, Jennie, Brightwell-Arnold, Mary, Harkins, Sandra, Peskin, Ellen, Ying, Gui‐Shuang , Kurinij, Natalie, Chen, Wei , Campochiaro, Peter A. , Conley, Yvette P. , Schwartz, Stephen G. , DeAngelis, Margaret M. , Chew, Emily Y. , Gorin, Michael B. , Menosky, Matthew M., Weinberg, David V. , Barr, Charles C. , Heier, Jeffrey S. , Capone, A. , Hassan, T. , McCannel, Colin A. , Blinder, Kevin J. , Holekamp, Nancy M. , Browning, David J. , Chambers, Robert , Altaweel, Michael M. , Maguire, Maureen G. , Weeks, Daniel E , Brion, María , Abecasis, Gonçalo

Mayo Clinic

Proceedings of the National Academy of Sciences | April 12, 2010 | Volume: 107 | Issue: 16 | Pages: 7401-7406

10.1073/pnas.0912702107 | PMID 20385819 Get It

We executed a genome-wide association scan for age-related macular degeneration (AMD) in 2,157 cases and 1,150 controls. Our results validate AMD susceptibility loci near CFH ( P < 10 −75 ), ARMS2 ( P < 10 −59 ), C2/CFB ( P < 10 −20 ), C3 ( P < 10 −9 ), and CFI ( P < 10 −6 ). We compared our top findings with the Tufts/Massachusetts General Hospital genome-wide association study of advanced AMD (821 cases, 1,709 controls) and genotyped 30 promising markers in additional individuals (up to 7,749 cases and 4,625 controls). With these data, we identified a susceptibility locus near TIMP3 (overall P = 1.1 × 10 −11 ), a metalloproteinase involved in degradation of the extracellular matrix and previously implicated in early-onset maculopathy. In addition, our data revealed strong association signals with alleles at two loci ( LIPC , P = 1.3 × 10 −7 ; CETP , P = 7.4 × 10 −7 ) that were previously associated with high-density lipoprotein cholesterol (HDL-c) levels in blood. Consistent with the hypothesis that HDL metabolism is associated with AMD pathogenesis, we also observed association with AMD of HDL-c—associated alleles near LPL ( P = 3.0 × 10 −3 ) and ABCA1 ( P = 5.6 × 10 −4 ). Multilocus analysis including all susceptibility loci showed that 329 of 331 individuals (99%) with the highest-risk genotypes were cases, and 85% of these had advanced AMD. Our studies extend the catalog of AMD associated loci, help identify individuals at high risk of disease, and provide clues about underlying cellular pathways that should eventually lead to new therapies.
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
Archer, Laura, Kornblith, Alice B., Grenier, Debjani, Perez, Edith A., Wolff, Antonio C. , Kastrissios, Helen , Berry, Donald A. , Hudis, Clifford A. , Muss, Hyman B. , Partridge, Ann H. , Gralow, Julie R. , Perez, Edith A. , Wang, Xiaofei , Winer, Eric P. , Wolff, Antonio C

Mayo Clinic

Journal of Clinical Oncology | April 6, 2010 | Volume: 28 | Issue: 14 | Pages: 2418-2422

10.1200/jco.2009.26.4671 | PMID 20368559 Get It

Purpose Patient adherence is critical in evaluating the effectiveness of an oral therapy. We sought to measure adherence among women randomly assigned to capecitabine in a preplanned substudy of a multicenter clinical trial. Patients and Methods Cancer and Leukemia Group B study CALGB 49907 was a randomly assigned trial comparing standard chemotherapy versus oral chemotherapy with capecitabine in patients age 65 years or older with early-stage breast cancer. We used microelectronic monitoring system (MEMS) caps on participants' capecitabine bottles to record pill bottle openings. Capecitabine was given in two divided daily doses for 14 consecutive days of a 21-day cycle for six cycles. Adherence was calculated as the number of doses taken divided by doses expected, taking into account toxicity-related dosing changes. A participant was defined as adherent if 80% or more of expected doses were recorded by MEMS. Results Overall, 161 patients were enrolled. Median age was 71 years (range, 65 to 89 years); 124 patients (83%) persisted with capecitabine to completion of planned protocol therapy. Adherence was 78% across all cycles, and adherence did not vary by cycle (P = .32). Twenty-five percent of participants took fewer than 80% of expected doses and were nonadherent. In a logistic regression model, participants with node-negative disease (P = .01) and mastectomy (P = .01) were more likely to be nonadherent. Adherence was not related to age, tumor stage, or hormone receptor status. Adherence was not significantly associated with relapse-free survival or grade 3 or 4 toxicity. Conclusion Most older women with early-stage breast cancer were adherent to short-term oral chemotherapy in a randomized clinical trial. Age was not associated with adherence.